BridgeBio Pharma Inc’s filing revealed that its Director HOMCY CHARLES J unloaded Company’s shares for reported $11.51 million on Aug 08 ’25. In the deal valued at $46.05 per share,250,000 shares were sold. As a result of this transaction, HOMCY CHARLES J now holds 966,674 shares worth roughly $49.61 million.
Then, HOMCY CHARLES J sold 50,000 shares, generating $2,400,000 in total proceeds. Upon selling the shares at $48.00, the Director now owns 916,674 shares.
Before that, Apuli Maricel sold 1,000 shares. BridgeBio Pharma Inc shares valued at $45,440 were divested by the Chief Accounting Officer at a price of $45.44 per share. As a result of the transaction, Apuli Maricel now holds 141,859 shares, worth roughly $7.28 million.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 0.27% to $51.32. Over the last five days, the stock has gained 10.18%. BridgeBio Pharma Inc shares have risen nearly 114.64% since the year began. Nevertheless, the stocks have risen 87.03% over the past one year. While a 52-week high of $51.86 was reached on 08/14/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 50.73, which if violated will result in even more drops to 50.13. On the upside, there is a resistance level at 51.79. A further resistance level may holdings at 52.25.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-07-31, dropping by -3.32 million shares to a total of 18.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 21.83 million shares. There was a decline of -17.9%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
